X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (133) 133
Publication (14) 14
Book / eBook (7) 7
Book Review (6) 6
Dissertation (4) 4
Newspaper Article (3) 3
Magazine Article (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (44) 44
oncology (42) 42
male (33) 33
female (31) 31
middle aged (30) 30
adult (28) 28
aged (27) 27
index medicus (27) 27
melanoma (27) 27
cancer (19) 19
melanoma - drug therapy (19) 19
immunotherapy (16) 16
metastasis (13) 13
antineoplastic agents - therapeutic use (12) 12
care and treatment (12) 12
analysis (11) 11
patients (11) 11
antibodies, monoclonal - therapeutic use (10) 10
immunology (10) 10
metastatic melanoma (10) 10
skin neoplasms - drug therapy (10) 10
article (9) 9
treatment outcome (9) 9
aged, 80 and over (8) 8
antibodies, monoclonal - adverse effects (8) 8
antineoplastic agents - adverse effects (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
cancer therapies (8) 8
clinical trials (8) 8
drug therapy (8) 8
ipilimumab (8) 8
neoplasms - drug therapy (8) 8
nivolumab (8) 8
research (8) 8
skin neoplasms - pathology (8) 8
studies (8) 8
therapy (8) 8
tumors (8) 8
blockade (7) 7
chemotherapy (7) 7
melanoma - pathology (7) 7
melanoma - secondary (7) 7
mutation (7) 7
neoplasms. tumors. oncology. including cancer and carcinogens (7) 7
solid tumors (7) 7
surgery (7) 7
usage (7) 7
drug administration schedule (6) 6
guidelines (6) 6
lymphocytes (6) 6
malignant-melanoma (6) 6
management (6) 6
open-label (6) 6
risk factors (6) 6
skin cancer (6) 6
antibodies, monoclonal - administration & dosage (5) 5
antineoplastic agents - administration & dosage (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
business (5) 5
cell lung-cancer (5) 5
disease-free survival (5) 5
dose-response relationship, drug (5) 5
immune-related adverse events (5) 5
interleukin-2 (5) 5
medical research (5) 5
medicine, general & internal (5) 5
medicine, research & experimental (5) 5
melanoma - genetics (5) 5
mice (5) 5
programmed cell death 1 receptor - antagonists & inhibitors (5) 5
t cells (5) 5
united states (5) 5
abridged index medicus (4) 4
adolescent (4) 4
body weight (4) 4
carcinoma, renal cell - drug therapy (4) 4
carcinoma, renal cell - therapy (4) 4
colony-stimulating factor (4) 4
disease (4) 4
health aspects (4) 4
interleukin-2 - therapeutic use (4) 4
invivo (4) 4
ligands (4) 4
lung cancer (4) 4
melanoma - immunology (4) 4
melanoma - mortality (4) 4
melanoma - therapy (4) 4
neoplasms - immunology (4) 4
pembrolizumab (4) 4
programmed cell death 1 receptor - immunology (4) 4
proto-oncogene proteins b-raf - genetics (4) 4
toxicity (4) 4
trial (4) 4
1900-1999 (3) 3
activated killer cells (3) 3
age (3) 3
alzheimer’s disease (3) 3
anti-pd-1 (3) 3
antigens (3) 3
apoptosis (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2012, Emerging cancer therapeutics, ISBN 1617051616, Volume 3, issue 3
Web Resource
Cell, ISSN 0092-8674, 11/2017, Volume 171, Issue 4, pp. 934 - 949.e16
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 26, pp. 2542 - 2552
Journal Article
by Lundqvist, Andreas and van Hoef, Vincent and Zhang, Xiaonan and Wennerberg, Erik and Lorent, Julie and Witt, Kristina and Sanz, Laia Masvidal and Liang, Shuo and Murray, Shannon and Larsson, Ola and Kiessling, Rolf and Mao, Yumeng and Sidhom, John-William and Bessell, Catherine A and Havel, Jonathan and Schneck, Jonathan and Chan, Timothy A and Sachsenmeier, Eliot and Woods, David and Berglund, Anders and Ramakrishnan, Rupal and Sodre, Andressa and Weber, Jeffrey and Zappasodi, Roberta and Li, Yanyun and Qi, Jingjing and Wong, Philip and Sirard, Cynthia and Postow, Michael and Newman, Walter and Koon, Henry and Velcheti, Vamsidhar and Callahan, Margaret K and Wolchok, Jedd D and Merghoub, Taha and Lum, Lawrence G and Choi, Minsig and Thakur, Archana and Deol, Abhinav and Dyson, Gregory and Shields, Anthony and Haymaker, Cara and Uemura, Marc and Murthy, Ravi and James, Marihella and Wang, Daqing and Brevard, Julie and Monaghan, Catherine and Swann, Suzanne and Geib, James and Cornfeld, Mark and Chunduru, Srinivas and Agrawal, Sudhir and Yee, Cassian and Wargo, Jennifer and Patel, Sapna P and Amaria, Rodabe and Tawbi, Hussein and Glitza, Isabella and Woodman, Scott and Hwu, Wen-Jen and Davies, Michael A and Hwu, Patrick and Overwijk, Willem W and Bernatchez, Chantale and Diab, Adi and Massarelli, Erminia and Segal, Neil H and Ribrag, Vincent and Melero, Ignacio and Gangadhar, Tara C and Urba, Walter and Schadendorf, Dirk and Ferris, Robert L and Houot, Roch and Morschhauser, Franck and Logan, Theodore and Luke, Jason J and Sharfman, William and Barlesi, Fabrice and Ott, Patrick A and Mansi, Laura and Kummar, Shivaani and Salles, Gilles and Carpio, Cecilia and Meier, Roland and Krishnan, Suba and McDonald, Dan and Maurer, Matthew and Gu, Xuemin and Neely, Jaclyn and Suryawanshi, Satyendra and Levy, Ronald and Khushalani, Nikhil and Wu, Jennifer and Zhang, Jinyu and Basher, Fahmin and Rubinstein, Mark and Bucsek, Mark and Qiao, Guanxi and ...
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 11/2016, Volume 4, Issue S1
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2443 - 2454
Releasing T cells from inhibitory control has been a strategy exploited by the anti–CTLA-4 antibody ipilimumab. Now an antibody against a second checkpoint... 
CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | THERAPY | SOLID TUMORS | RESPONSE CRITERIA | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | ANTITUMOR IMMUNITY | BLOCKADE | Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Ligands | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Immune response | Anti-antibodies | Dosage and administration | Product/Service Evaluations | Regulation | Research | Drug therapy | Cancer | Fees & charges | Kidneys | Stock options | PD-1 protein | Laboratories | Toxicity | Tumor cells | Body weight | Lung cancer | Colorectal carcinoma | Colorectal cancer | Melanoma | Licenses | Lymphocytes T | Patients | Castration | PD-L1 protein | Antitumor activity | Prostate cancer | Drug dosages | Prostate | Clear cell-type renal cell carcinoma | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Biologics: Targets and Therapy, ISSN 1177-5475, 11/2015, Volume 9, pp. 129 - 140
Looks at the role of Vismodegib (GDC-0449), a smoothened inhibitor targeted at the hedgehog pathway, as the first US Food and Drug Association (FDA)-approved... 
Hedgehog | Smoothened | Basal cell carcinoma | Basal cell nevus syndrome | Vismodegib | Gorlin | Treatment | Cancer | Biologicals | Complications and side effects | Care and treatment | Squamous cell carcinoma | Analysis | Mortality | Research | Drug approval | Risk factors | Internal medicine | Dermatology | Surgery | Metastasis | Mutation | Kinases | Patients | Cancer therapies | Tumors | Skin cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2010, Volume 28, Issue 19, pp. 3167 - 3175
Journal Article
by Puzanov, I and Diab, A and Abdallah, K and Bingham, C.O and Brogdon, C and Dadu, R and Hamad, L and Kim, S and Lacouture, M.E and LeBoeuf, N.R and Lenihan, D and Onofrei, C and Shannon, V and Sharma, R and Silk, A.W and Skondra, D and Suarez-Almazor, M.E and Wang, Y and Wiley, K and Kaufman, H.L and Ernstoff, M.S and Anderson, Jeff and Lehman, Kimberly and Reshef, Dan and Saylors, Ann and Turner, Michelle and Waxman, Ian and Arrindell, Deborah and Andrews, Stephanie and Ballesteros, Joan and Boyer, Janie and Cotarla, Ion and Dawson, Michelle and Goswami, Trishna and Hayreh, Vinny and Holmes, William and Rasheed, Zeshaan and Sarkeshik, Makan and Schreiber, Judy and Shafer-Weaver, Kim and Chen, Daniel and Ley-Acosta, Sergio and Chonzi, David and Go, William and Cunha, Renato and Gulley, James L and Wood, Lauren and Davies, Marianne and Dicker, Adam and Eifler, Lisa and Gregory, Nancy and Ferguson, Andrew and Ferlini, Cristiano and Frankel, Stanley and Gochett, Celestine and Goldberg, Jenna and Patel, Kiran and Wariabharaj, Darshan and Goncalves, Priscila and Helie, Nicole and Hsu, Jer-Yuan and Ibrahim, Ramy and Larocca, Cecilia and Lambotte, Olivier and Luke, Jason and McClure, Joan and Michelon, Elisabete and Nakamura, Mary and Piperdi, Bilal and Riemer, Joanne and Robert, Caroline and Sharfman, William and Sharon, Elad and Sherry, Richard and Simonson, Cyndy and Thomas, Cherry and Trehu, Elizabeth and Thompson, John A and Tresnan, Dina and Zhang, Lin and Zheng, Pan and Soc Immunotherapy Canc Toxicity M and Society for Immunotherapy of Cancer Toxicity Management Working Group and on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 11/2017, Volume 5, Issue 1, pp. 95 - 28
Journal Article
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 02/2019, Volume 7, Issue 1, pp. 40 - 8
BackgroundSeveral predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1... 
Neoantigens | T cells | Checkpoint blockade | Oncogene | Predictive biomarkers | DOMAIN | PD-1 BLOCKADE | BRAF | IMMUNOLOGY | CANCER | TUMORS | ONCOLOGY | AFFINITY | AKT1 | MUTATIONS | BINDING | Medical research | Immunotherapy | Colorectal cancer | Medicine, Experimental | Genetic aspects | Lung cancer, Non-small cell | Tumors | Lymphocytes | Lung cancer | Genomics | Melanoma | Biomarkers | Ligands | Mutation | Patients | Cancer therapies
Journal Article